Amgen Announces $900 Million Worth Expansion of Manufacturing Facility in the US
Amgen has made about $5 billion in direct capital investments in the US since the Tax Cuts and Jobs Act of 2017 was passed.
Category: News
Roche Released Phase III CENTERSTONE Trial Data Showing Treatment With Xofluza Reduces Influenza Virus Transmission
CENTERSTONE is the first worldwide phase III trial that shows how effective an antiviral medication is at slowing the spread of a respiratory virus.
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for TrenibotulinumtoxinE (TrenibotE), Treating Glabellar Lines
AbbVie declared that they had submitted the Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE) to the United States FDA for the treatment of moderate to severe glabellar lines. [Read More…]
Roche to Invest USD 50 Billion in United States for Pharmaceuticals and Diagnostics Over the Next Five Years
More than 12,000 new jobs will be created by investments, including 1,000 at Roche and more than 11,000 to support the development of new manufacturing capabilities in the US.
Gliead Releases the Results of Phase 3 ASCENT-04/KEYNOTE-D19 Trials Shows Positive Effect for Combinational Use of Trodelvy® Plus Keytruda®
The trial achieved its main goal with a statistically significant and clinically relevant improvement in PFS.
European Commission Approves Roche’s Columvi® (glofitamab) For B-cell Lymphoma Based on the Phase III STARGLO Study Results
Columvi therapy provides a much-needed, off-the-shelf, fixed-duration alternative for transplant ineligible individuals.
Dupixent (Dupilumab), Sanofi’s New Targeted Therapy For Chronic Spontaneous Urticaria Approved by the U.S. FDA
Phase 3 tests showing Dupixent dramatically decreased itching and hives when compared to a placebo led to approval.
Eli Lilly’s Orforglipron, an Investigational Oral GLP-1 Weight-loss and Diabetes Pill Shows Similar Efficacy Results of Their Injectable GLP-1
In a Phase 3 trial, orforglipron, the first small molecule GLP-1, successfully reduced A1C by an average of 1.3% to 1.6% across dosages.
European Union Grants Marketing Approval for Biogen’s Leqembi® an Amyloid-beta (Aβ) Monoclonal Antibody
Lecanemab is the only approved Aβ monoclonal antibody that binds and clears hazardous protofibrils.
Eyestem’s Eyecyte-RPE™ Trial Shows Vision Rescue for Geographic Atrophy Patients
All nine subjects of phase 1 injected without any serious adverse events.
